Improvement in the undertreatment of osteoporosis following hip fracture
- PMID: 12177263
- DOI: 10.2106/00004623-200208000-00008
Improvement in the undertreatment of osteoporosis following hip fracture
Abstract
Background: Osteoporosis is a common disease characterized by decreased bone mass and increased fracture risk in postmenopausal women and the elderly. Hip fractures are among the most common consequences of osteoporosis and unfortunately usually occur late in the course of the disease. When a patient is admitted to the hospital with a fragility hip fracture, a unique opportunity for diagnosis and treatment presents itself. Fortunately, several medications have proven to be effective in lowering the risk of future fractures. The purposes of the present study were to test the hypothesis that most fragility hip fractures go untreated and to determine whether educational efforts to raise physician awareness have led to an improvement in osteoporosis treatment rates.
Methods: A retrospective cohort study was performed with use of the patient databases at two university medical centers and one university-affiliated community hospital. The charts of 300 randomly selected patients were sorted with use of ICD-9 (International Classification of Diseases, Ninth Revision) codes for femoral neck fractures. There were 100 patients from each center, with twenty-five patients from each year between 1997 and 2000. The admitting diagnosis, mechanism of injury, admission medications, procedures performed during hospitalization, and discharge medications were then extracted and analyzed. During this period, the National Osteoporosis Foundation established guiding principles for the treatment of fragility fractures.
Results: Of the seventy-five patients from all centers for each year from 1997 to 2000, 11%, 13%, 24%, and 29%, respectively, were discharged with a prescription for some medication targeting osteopenia, either supplemental calcium or an antiosteoporotic medication (estrogen, calcitonin, a bisphosphonate, or raloxifene). A trended chi-square analysis of this increase revealed a p value of <0.001, indicating that this improvement in treatment was unlikely due to chance alone. Fifty-eight (19.3%) of the 300 patients in the study received a prescription at the time of discharge. However, forty of these patients (13.3% of the overall group) received calcium and only eighteen (6.0% of the overall group) received a medication to actively prevent bone resorption and treat osteoporosis. In addition, no patient underwent a bone density scan while in the hospital.
Conclusions: Elderly patients and postmenopausal women who are admitted to the hospital and diagnosed with a low-energy femoral neck fracture have been undertreated for osteoporosis. However, over the four years of the present study, there was a significant increase in the rate of treatment. It is hoped that treatment rates will continue to increase in the future with continued educational efforts.
Comment in
-
Undertreatment of osteoporosis following hip fracture.J Bone Joint Surg Am. 2003 Jul;85(7):1394-5; author reply 1395-6. doi: 10.2106/00004623-200307000-00041. J Bone Joint Surg Am. 2003. PMID: 12851373 No abstract available.
Similar articles
-
Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.Osteoporos Int. 2003 Sep;14(9):741-9. doi: 10.1007/s00198-003-1432-1. Epub 2003 Jun 19. Osteoporos Int. 2003. PMID: 12827224 Clinical Trial.
-
The management of osteoporosis following hip fracture: have we improved our care?Osteoporos Int. 2003 Nov;14(11):884-8. doi: 10.1007/s00198-003-1492-2. Epub 2003 Oct 16. Osteoporos Int. 2003. PMID: 14569422
-
Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture.J Am Geriatr Soc. 2010 Apr;58(4):650-7. doi: 10.1111/j.1532-5415.2010.02769.x. J Am Geriatr Soc. 2010. PMID: 20398147 Free PMC article.
-
Pharmacological management of severe postmenopausal osteoporosis.Drugs Aging. 2005;22(5):405-17. doi: 10.2165/00002512-200522050-00005. Drugs Aging. 2005. PMID: 15903353 Review.
-
Raloxifene: a review of its use in postmenopausal osteoporosis.Drugs. 2000 Aug;60(2):379-411. doi: 10.2165/00003495-200060020-00013. Drugs. 2000. PMID: 10983739 Review.
Cited by
-
Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec.BMC Musculoskelet Disord. 2005 Jun 21;6:33. doi: 10.1186/1471-2474-6-33. BMC Musculoskelet Disord. 2005. PMID: 15969760 Free PMC article.
-
The management of osteoporosis following hip fracture: how to improve our care.Osteoporos Int. 2004 Jul;15(7):583-4. doi: 10.1007/s00198-004-1645-y. Osteoporos Int. 2004. PMID: 15138666 No abstract available.
-
Brigham fracture intervention team initiatives for hospital patients with hip fractures: a paradigm shift.Int J Endocrinol. 2010;2010:590751. doi: 10.1155/2010/590751. Int J Endocrinol. 2010. PMID: 20011097 Free PMC article.
-
Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior's residences.Wien Klin Wochenschr. 2010 Sep;122(17-18):532-7. doi: 10.1007/s00508-010-1428-8. Epub 2010 Aug 23. Wien Klin Wochenschr. 2010. PMID: 20730567
-
A population-based analysis of the post-fracture care gap 1996-2008: the situation is not improving.Osteoporos Int. 2012 May;23(5):1623-9. doi: 10.1007/s00198-011-1630-1. Epub 2011 Apr 8. Osteoporos Int. 2012. PMID: 21476038
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical